GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships

Authors: Daemmrich, Arthur A.; Cornell, Ian McKown
Source: Harvard Business School
Year: 2012
Company Name: GlaxoSmithKline
Number of pages: 15

[This document has not yet been rated] [You must be signed in as faculty to rate this document]   276 views

Abstract:

Three years into a major public-private partnership between GlaxoSmithKline and Fiocuz, Brazil's principal health institute, the company assesses technology transfer and joint research under the agreement. GSK was selling its Synflorix vaccine (against pediatric pneumonia) at fixed prices even as it transferred technology and know-how to Brazil for eventual domestic production. At the same time, GSK was co-sponsoring research into a new vaccine for Dengue fever with the Brazilian government. GSK's management must consider whether the PPP provides strategic advantage to its consumer healthcare businesses in Brazil and to access other emerging markets as well as the risks posed by the aggressive product obsolescence built into the technology transfer agreement.